

MEDISTEM LABORATORIES, INC.  
Form 8-K  
May 20, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**May 20, 2008**

**Date of Report (Date of earliest event reported)**

Medistem Laboratories, Inc.

**(Exact name of registrant as specified in its charter)**

Nevada	333-100137	86-1047317
<b>(State or other jurisdiction</b>	<b>(Commission File Number)</b>	<b>(IRS Employer Identification</b>
<b>of incorporation)</b>		<b>No.</b>

2223 West Pecos Road, Suite 6, Chandler, Arizona

85224

(Address of principal executive offices)

(Zip Code)

**Registrant's telephone number, including area code:** (954) 727-3662

Not applicable.

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 16, 2008, Chris McGuinn resigned from his position as Chief Operating Officer of Medistem Laboratories, Inc. (the Company) to pursue other business opportunities. On May 20, 2008, the Company issued a press release announcing Mr. McGuinn's resignation. The full text of the Company's press release is attached hereto as Exhibit 99.1. The Company has no current plans for replacing Mr. McGuinn and for the time being will divide his responsibilities among its existing employees.

**Item 9.01. Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release regarding Chris McGuinn's resignation, dated May 20, 2008.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDISTEM LABORATORIES, INC.

Date: May 20, 2008

By: /s/ Steve Rivers

Name: Steve Rivers

Title: Chief Financial Officer

